A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Australia, China, France, Germany, Hong Kong, Italy, Poland, Singapore, South Korea, Spain, and Taiwan73 sites in 11 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 280 people enrolled
- Started
- 6 Mar 2024
- Ended
- 22 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Faricimab
- Ranibizumab
- Sham Procedure
- Record updated
- 31 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Treatment-naïve choroidal neovascularization (CNV) secondary to myopia
- Diagnosis of active myopic CNV in the study eye:; Presence of high myopia, worse than -6 diopters of spherical equivalence; Antero-posterior elongation measurement greater than or equal to 26.0 mm; Presence of posterior changes compatible with pathologic myopia (e.g., tessellated fundus, lacquer cracks, etc.); Presence of active leakage from CNV on FFA (determined by Central Reading Centre [CRC]); Presence of intraretinal or subretinal fluid or increase of CST on OCT (determined by CRC)
- BCVA of 78 to 24 letters, inclusive (20/32 to 20/320 approximate Snellen equivalent), using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol on Day 1
- Overtly healthy as determined by medical evaluation that includes medical history, physical examination, and laboratory tests
- Ability to comply with the study protocol, in the Investigator's judgment
- Other protocol-defined inclusion criteria apply
Who cannot take part
- Any major illness or major surgical procedure within 1 month before screening
- Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1
- History of systemic or ocular disease that would contraindicate treatment with the investigational drug or comparator
- Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities, including, but not restricted to, intravitreal, periocular or laser interventions in study eye
- Prior or concomitant periocular or intravitreal pharmacological treatment, including anti-VEGF medication, for other retinal diseases (e.g. geography atrophy, nAMD, DME etc.) in study eye
- Pregnancy or breastfeeding, or intention to become pregnant during the study or within 3 months after the final study treatment administration
- Uncontrolled blood pressure (systolic >180 millimetres of mercury [mmHg], diastolic >100 mmHg)
- Uncontrolled glaucoma in study eye
- Other protocol-defined exclusion criteria apply
This trial has no sites in United States.
It has sites in 11 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
The 2 groups in the trial
- Arm A: FaricimabTreatment being tested
All participants randomly assigned to Arm A will receive faricimab 6 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with faricimab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.
Treatment: Faricimab and Sham Procedure
- Arm B: RanibizumabExisting treatment, for comparison
All participants randomly assigned to Arm B will receive ranibizumab 0.5 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with ranibizumab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.
Treatment: Ranibizumab and Sham Procedure
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Record updated
- 31 July 2026